Eric Rose, M.D., Named Chairman of the CircuLite® Board of Directors
SADDLE BROOK, N.J.--(BUSINESS WIRE)--Oct 10, 2012--CircuLite®, Inc. today announced the appointment of Eric Rose, M.D., as Chairman of its Board of Directors. Dr. Rose is a recognized leader in academic medicine and surgery and an entrepreneur. His interests range from device development to drug discovery, biodefense, clinical evaluative research and health policy. He is Executive Vice President of Life Sciences at MacAndrews & Forbes and has been a Director of CircuLite since November 2011.
“Dr. Rose is a pioneer in the field of cardiac surgery and has been influential in the advancement of mechanical circulatory support technologies since the early formation of this field. We are pleased to have his insight and direction as our Chairman,” said Paul Southworth, President and CEO of CircuLite. “Dr. Rose’s unique perspective will help guide us as we seek to address the needs of a large segment of heart failure patients who are not responding to standard medical care and have no other treatment options.” “CircuLite’s SYNERGY® System presents a multi-faceted opportunity that extends from the small size and minimally invasive nature of the implant procedure. Not only is it designed to address a large unmet clinical need, but it has the potential to reduce healthcare costs for hospitals compared to traditional assist devices,” said Dr. Rose. “In CircuLite’s CE Mark study, patients demonstrated significant improvements in hemodynamics, exercise tolerance and quality of life, in addition to typically shorter overall hospitalizations compared to traditional assist devices. I look forward to continuing to work with the CircuLite team as they commercialize the SYNERGY System in new markets and advance additional platform applications to maximize benefits for patients and stakeholders alike.” In addition to his work with MacAndrews & Forbes, Dr. Rose has been Chairman of the Department of Health Policy at the Mount Sinai School of Medicine since 2008. He has also served as a director of SIGA Technologies since 2001, becoming Chairman and CEO in 2007. From 1994 to 2007, he was Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. Dr. Rose is a past President of the International Society for Heart and Lung Transplantation and was also the Morris & Rose Millstein Professor of Surgery at Columbia University’s College of Physicians and Surgeons’ Department of Surgery. In 1984, Dr. Rose performed the first successful pediatric heart transplant at Columbia University. He later organized and led the NIH-funded REMATCH trial, which was the first study to demonstrate the long-term benefits of mechanical circulatory support devices in non-transplantable, end-stage heart disease patients. Dr. Rose has a M.D. from Columbia University College of Physicians & Surgeons and a B.A. from Columbia University.
CircuLite is developing disruptive solutions to improve the treatment of heart failure. The Company’s technologies work in conjunction with the heart to enhance clinical outcomes and improve quality of life. SYNERGY®, which recently received CE Marking approval, features the smallest surgically implanted blood pump for long-term use in patients with heart failure not responding to standard medical treatment. For more information, visit our website at www.circulite.net.
CAUTION: Investigational Device. Limited by United States Law to Investigational Use Only.
CircuLite® and SYNERGY® are registered trademarks of CircuLite, Inc. in the United States.CONTACT: MacDougall Biomedical Communications Kari Watson and Cory Tromblee, 781-235-3060 firstname.lastname@example.org@macbiocom.com or CircuLite, Inc.: Gail Farnan, 201-478-7651 Vice President, Marketing KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY INDUSTRY KEYWORD: HEALTH CARDIOLOGY MEDICAL DEVICES SOURCE: CircuLite Copyright Business Wire 2012 PUB: 10/10/2012 09:00 AM/DISC: 10/10/2012 09:00 AM http://www.businesswire.com/news/home/20121010005791/